Skip to main content
SpringerLink
Log in

Référentiels inter régionaux en Soins Oncologiques de Support

Symptômes articulaires liés aux traitements du cancer

  • Référentiels De Pratiques / Guidelines
  • Published:
Oncologie

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliographie

  • Perrot S, Javier R.M, Marty M., Medjda O, Tournigand C, Laroche F et le CEDR (cercle d’étude de la douleur en rhumatologie) (2009) Atteintes ostéo-articulaires induites par les traitements par anti-aromatases au cours du cancer du sein. La Lettre du Rhumatologue, n° 357-décembre 2009

    Google Scholar 

  • Lesur A, Barlier C (2012) Arthralgies, effets secondaires, des inhibiteurs de l’aromatase: fréquence, signification et conséquences. Oncologie 14: 365–373

    Article  CAS  Google Scholar 

  • Scotté F (2012) Troubles musculo-squelettiques hormono-induits, compte-rendu et analyse Chicago. La Lettre du Cancérologue (Supplément 2) XXI(6): 76–83

    Google Scholar 

  • Sestak I, Sapunar F, Cuzick J (2009) Aromatase Inhibitor–Induced Carpal Tunnel Syndrome: Results From the ATAC Trial Journal of Clinical Oncology 27(30): 4961–65

    Article  CAS  PubMed  Google Scholar 

  • Sestak I, Cuzick J, Sapunar F., et al. (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 9: 866–72

    Article  PubMed  Google Scholar 

  • Boccardo F, Rubagotti A, Puntoni M. et al. (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. Journal of Clinical Oncology 23(22): 5138–47

    Article  CAS  PubMed  Google Scholar 

  • Jakesz R, Jonat W, Gnant M et al. (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484): 455–62

    Article  CAS  PubMed  Google Scholar 

  • Jakesz R, Greil R, Gnant M et al. (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 99(24): 1845–53

    Article  CAS  PubMed  Google Scholar 

  • Briot K, Tubiana-Hulin M, Bastit L, et al. (2010) Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptorpositive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast cancer research and treatment 120: 127–134

    Article  CAS  PubMed  Google Scholar 

  • BIG 1-98 Collaborative Group, Mouridsen H et al. (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 361(8): 766–76

  • Goss PE, Ingle JN, Martino S, et al. (2005) Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. Journal of the National Cancer Institute 97(17): 1262–71

    Article  CAS  PubMed  Google Scholar 

  • Coombes RC, Kilburn LS, Snowdon CF, et al. (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 369(9561): 559–70. Erratum in: Lancet. (2007) 369(9565): 906

    Article  CAS  PubMed  Google Scholar 

  • Mieog JS, Morden JP, Bliss JM, et al. (2012) Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol. 13(4): 420–32.

    Article  PubMed  Google Scholar 

  • Jones SE, Cantrell J, Vukelja S, and al. (2007) Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol. 25(30): 4765–71

    Article  CAS  PubMed  Google Scholar 

  • Van de Velde CJ, Rea D, Seynaeve C, et al. (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762): 321–31

    Article  PubMed  Google Scholar 

  • Crew KD, Greenlee H, Capodice J, et al. (2007) Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer. Journal of Clinical Oncology 25: 3877–83

    Article  PubMed  Google Scholar 

  • Vanlemmens L, Biver E, Gérot Legroux I et al. (2009) ATOS: Etude observationnelle, en situation réelle, du retentissement ostéo-articulaire des antiaromatases en adjuvant d’un cancer du sein. Poster SFSPM

    Google Scholar 

  • Vanlemmens L, Biver E, Gérot Legroux I, Vieillard MH et al. (2010) Are arthralgia observed in patients treated with adjuvant aromatase inhibitors (AI) for breast cancer related to inflammatory rheumatism? Rheumatologic evaluation of a cohort of 41 patients. Poster EBCC

    Google Scholar 

  • Monnier A (2007) Clinical Management of adverse events in adjuvant therapy for hormone-responsive early breast cancer Annals of Oncology 18 (Suppl 8): viii36–viii44

    PubMed  Google Scholar 

  • Perez EA (2007) Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Annals of Oncology 18 (Suppl 8): viii26–viii35

    PubMed  Google Scholar 

  • Coleman RE, Bolten WW, Lansdown M, et al. (2008) Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treatment Reviews 34: 275–82

    Article  CAS  PubMed  Google Scholar 

  • Morales L, Pans S, Verschueren K, et al. (2008) Prospective Study to Assess Short-Term Intra-Articular and Tenosynovial Changes in the Aromatase Inhibitor–Associated Arthralgia Syndrome. Journal of Clinical Oncology 26 (19): 3147–52

    Article  PubMed  Google Scholar 

  • Niravath P. (2013) Aromatase inhibitor-induced arthralgia: a review. Annals of Oncology 24 (6): 1443–49

    Article  CAS  PubMed  Google Scholar 

  • Din OS, Dodwell D, Wakefield RJ, Coleman RE (2010) Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat. 120:525–538

    Article  CAS  PubMed  Google Scholar 

  • Din OS, Dodwell D, Winter MC, et al. (2011) Current Opinion of Aromatase Inhibitor-induced Arthralgia in Breast Cancer in the UK. Clinical Oncology 23: 674–680

    Article  CAS  PubMed  Google Scholar 

  • Gaillard S and Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Research 13: 205

    Article  CAS  Google Scholar 

  • Binkley JM, Harris SR, Levangie PK, et al. (2012) Patient Perspectives on Breast Cancer Treatment Side Effects and the Prospective Surveillance Model for Physical Rehabilitation for Women With Breast Cancer. Cancer: 118(S8): 2207–16

    Article  PubMed  Google Scholar 

  • Saibil S, Fitzgerald B, Freedman OC et al. (2010) Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol. 17(4): 42–7

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Schönherr A, Aivazova-Fuchs V, Annecke K, et al. (2012) Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer. Breast Care (Basel) 7(4): 289–95.

    Article  Google Scholar 

  • Eiermann W, Pienkowski T, Crown J, et al. (201) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 29(29): 3877–84

  • Martin M, Lluch A, Segui MA, et al. (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Annals of Oncology 17(8): 1205–12

    Article  CAS  PubMed  Google Scholar 

  • Klotz L, Boccon-Gibod L, Shore ND, et al. (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 102(11): 1531–8

    Article  CAS  PubMed  Google Scholar 

  • Tannock IF, de Wit R, Berry WR et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351(15): 1502–12

    Article  CAS  PubMed  Google Scholar 

  • De Bono JS, Oudard S, Ozguroglu M, et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747): 1147–54

    Article  PubMed  Google Scholar 

  • Imai A, Matsunami K, Takagi H, Ichigo S. (2012) Proposed medications for taxane-induced myalgia and arthralgia (Review). Oncology Letters 3: 1181–85

    PubMed Central  CAS  PubMed  Google Scholar 

  • Menas P, Merkel D, Hui W, et al. (2012) Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. Journal of Oncology Pharmacy Practice 18: 387–93.

    Article  CAS  PubMed  Google Scholar 

  • Schmitz KH, Speck RM, Rye SA,et al. (2012) Prevalence of Breast Cancer Treatment Sequelae Over 6 Years of Follow-Up. Cancer 118(S8): 2217–25.

    Article  PubMed  Google Scholar 

  • Winters-Stone KM, Schwartz AL, Hayes SC, et al. (2012) A Prospective Model of Care for Breast Cancer Rehabilitation: Bone Health and Arthralgias. Cancer 118(S8): 2288–99

    Article  PubMed  Google Scholar 

  • Fenlon D, Addington-Hall JM, O’Callaghan AC, et al. (2013) A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer. Journal of Pain and Symptom Management 46 (4): 523–35.

    Article  PubMed  Google Scholar 

  • Bondarenko et al. (2013) Efficacity and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin: docetaxel chemotherapy. BMC cancer 13:386

  • Kirshner JJ, Heckler CE, Janelsins Mc et al. (2012) Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol. 30: 1974–79

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Pinto L, Liu Z, Doan Q, et al. (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 23(9): 2283–95

    Article  CAS  PubMed  Google Scholar 

  • Fizazi K, Carducci M, Smith M et al. (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377: 813–22

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Henry DH, Costa L, Goldwasser F et al. (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 29: 1125–32

    Article  CAS  PubMed  Google Scholar 

  • Stopeck AT, Lipton A, Body JJet al. (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28(35): 5132–9

    Article  CAS  PubMed  Google Scholar 

  • Morales L, Pans S, Paridaens R and al. (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Research and Treatment 104(1): 87–91

    Article  CAS  PubMed  Google Scholar 

  • Irwin ML, Cartmel B, Gross C, et al. (2013) Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: The hormones and physical exercise (HOPE) study. Paper presented at: 36th Annual San Antonio Breast Cancer Symposium. Abstract S3–03

    Google Scholar 

Download references

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Référentiels inter régionaux en Soins Oncologiques de Support. Oncologie 17, 411–433 (2015). https://doi.org/10.1007/s10269-015-2549-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-015-2549-5

Search

Navigation